» Advanced search
Only first 10,000 results will be saved in the file.
No item is selected. Use checkboxes to select search results.
Displaying 276-300 of 1083 results.
 
{{ selectedCountPage }} items selected on this page, {{ selectedCountPage }} item selected on this page, {{ selectedCountTotal }} item in total {{ selectedCountTotal }} items in total
manifestations and laboratory findings of patients with Covid-19. Design: Double blind, randomized clinical trial, with control group, with a parallel group design of 90 patients with Covid-19. Settings and (...) patients with Covid-19
IRCTID: IRCT20120109008665N14
  1. Study of Tocilizumab effect on treatment and clinical symptoms and laboratory signs of Iranian COVID-19 patients: a ‎crinical trial study
  2. Evaluating efficacy of Kelofan syrup, a traditional Iranian medicine product on pulmonary & other clinical and laboratory manifestations of patients with or probable of covid-19
  3. Evaluating efficacy of Kelofan syrup, a traditional Iranian medicine product, on pulmonary and other clinical and laboratory manifestations of patients with probable or confirmed COVID-19
  4. Evaluation of herbal compound containing Anacyclus pyrethrum, Senna, Ferrula asafoetida and Terminalia chebula in COVID19: A randomized clinical trial study
  5. The effect of propolis supplementation on clinical manifestations and inflammatory biomarkers in patients with COVID-19
  6. Evaluation of the effects of Losartan in patients with corona virus disease 2019
  7. The effects of Ginger on clinical manifestations and paraclinical features of patients with COVID-19: A randomized double-blind placebo-control clinical trial
  8. Ginger (Zingiber officinale) and turmeric supplementation effects on quality of life, bone mineral density, body composition and osteoporosis related biomarkers and micro-RNAs in women with postmenoposal osteoporosis
  9. Investigating effect of Spirulina (Arthrospira platensis) dietary supplementation on COVID-19 disease outcomes in patients admitted to Intensive Care Units of hospitals: phase 2 clinical trial
  10. Evaluation of SinaCurcumin as a complementary therapy in mild to moderate COVID-19: An open label non-randomized clinical trial
Criteria:patients of COVID-19 with positivepolymerase chain reaction (PCR) test;Lack of hospitalization indication (...) hyperimmune bovine milk and colostrum will be orally tested on a group of referral COVID-19 patients to PCR (...) Study aim: Comparison of the Effectiveness of COVID-19specific antibody in hyperimmune bovine milk
IRCTID: IRCT20200927048849N3
findings and inflammatory markers in patients with Covid 19 Design: Clinical trial with control group (...) conduct: setting of study is Family hospital of army .In this study, 200 newly diagnosed COVID-19 (...) PCR for Covid 19 2. Existence of at least two of the following findings: RR>20, SO2<93%, GGO>10
IRCTID: IRCT20210803052060N1
with Covid-19 Design: The randomized double-blind clinical trial, with parallel design in phase 3 (...) will be performed on adult patients (aged 18 to 75 years) with a definitive diagnosis of COVID-19 (...) treatment of Covid 19 disease in the outpatient and inpatient services of the Ministry of Health and Medical
IRCTID: IRCT20200426047206N4
Study aim: The effect of olfactory training on anosmia following COVID-19 infection Design: Patients between the ages of 18-60 years following COVID-19 infection with olfactory dysfunction and a (...) and exclusion criteria: Inclusion Criteria: Patients between 18-60 years old following COVID-19
IRCTID: IRCT20200629047953N1
hospitalized patients with moderate to severe COVID-19. Design: This is a parallel 2-arm randomized (...) criteria: All moderate to severe COVID-19 infected patients admitted to Ema Reza hospital (Mashhad (...) moderate to severe COVID-19 in a 1:1 ratio: • Combination of traditional medicine+standard treatment
IRCTID: IRCT20200607047675N1
Covid-19 ‎admitted to critical care unit Design: The study will be double blind and clinical trial.64 (...) and conduct: Patients with Covid-19 with moderate disease severity (with Apache score above 25 (...) criteria:Suffering Covid-19 without intubation, apache less than 25, 28 to 75 years, absence of acute asthma, absence
IRCTID: IRCT20141209020258N165
Study aim: Study the effect of Favipiravir on the outpatient treatment Covid-19 patients Design: 70 outpatient patients with covid-19 will be randomly assigned to intervention and control (placebo (...) criteria: definite case of Covid-19, age over 18, presented within 5 days from the start of sign and
IRCTID: IRCT20171219037964N3
) supplement on COVID-19 disease's outcomes (consisted of laboratory measures ; ventilator free days;) LOS ICU (...) group, randomization using Random Number Table, phase 2 on patients with COVID-19 Settings and conduct: The study will be carried out among COVID-19 patients admitted in ICU hospitals. Spirulina supplement
IRCTID: IRCT20200720048139N1
  1. A clinical trial to compare the effectiveness of the Spirulina platensis algae (Arthrospira, blue-green algae) and N-acetyl cysteine with standard treatment in patients with COVID-19 infection
  2. Investigating the effect of training and spirulina supplement (Arthrospira platensis) on inflammatory status, oxidative stress, clinical symptoms, mental health and quality of life of women with migraine
  3. The effects of spirulina (Arthrospira platensis) supplementation compared to placebo on craving, mental health, sexual and cognitive function in opioid patients under methadone maintenance treatment
  4. Effect of Spirulina supplement (Arthrospira platensis) on disease activity indices, quality of life, mood, fatigue, serum antioxidant status and serum pentraxin 3 levels in patients with ulcerative colitis
  5. The effects of Spirulina Platensis on anemia status in patients with ulcerative colitis
  6. The effects of oral administration of Spirulina Platensis (cultured Iranian) on blood glucose and glycosylated Hemoglobin blood in type II diabetes mellitus patients
  7. Evaluation of oxidative stress biomarkers in type 2 diabetic patients consuming fermented and non-fermented spirulina platensis
  8. The Effect of Supplementation with Spirulina Platensis Algae on Serum Vascular Endothelial Growth Factor (VEGF) and Lipid Profile in Obese Individuals
  9. Effect of Spirulina as a nutritional supplement and drug in Covid-19 patients
  10. Effect of spirulina platensis supplementation on quality of life, severity of disease and serum total antioxidant capacity (TAC), manoldialdehyde (MDA) and zonulin in Irritable bowel syndrome patients (IBS)
symptoms of patients with mild COVID-19 Design: This study is a single-center, prospective, randomized (...) COVID-19; Confirmed diagnosis of COVID-19, with RT-PCR confirmation; Less than 7 days have passed since (...) Qovid-19 referred to Baqiyatallah Hospital who are eligible for the study are randomly divided into
IRCTID: IRCT20080901001165N63
overload caused by COVID-19 viral infection. Design: In this study, the intervention, which is done as a randomized clinical trial, selected 78 patients with covid 19 virus who were randomly assigned to two groups (...) : People with COVID 19 are referred to the Corona ward in Shohada Tajrish Hospital and are treated with
IRCTID: IRCT20190121042444N3
Study aim: Investigation of effect of pulsed ultrasound on smell disorder in recovered patients of COVID 19 getting better of variable of smell disorder in recovered patients of COVID 19 based on IRAN (...) Participants/Inclusion and exclusion criteria: age range:18 to 65 pass of 3 month of recovery or COVID 19
IRCTID: IRCT20220406054434N1
Study aim: Determining the effect of Covid 19 vaccine injection on calprotectin levels in patients (...) severity will be evaluated and compared before and after the injection of the Covid-19 vaccine. These (...) bowel disease are evaluated for calprotectin levels before and after the Covid-19 vaccination. Main
IRCTID: IRCT20210113050024N3
  1. Safety evaluation of a quadrivalent recombinant influenza vaccine (serotypes of 2021/2022) manufactured by Nivad Pharmed Salamat, open label, single arm, in volunteers aged ≥ 18 years.
  2. A randomized placebo-controlled double blind study to evaluate intradermal vaccination in hepatitis B healthy carriers to eliminate virus
  3. A phase III, Randomized, Two-armed, Double-blind, Placebo controlled trial to evaluate efficacy and safety of an adjuvanted recombinant SARS-CoV-2 spike (S) protein subunit vaccine (SpikoGen®) produced by CinnaGen Co. (Two doses of 25µg with dosing interval of 21 days)
  4. Evaluation of the serological response to the heterologous versus homologous booster vaccinationin in patients receiving autologous hematopoietic stem cell transplantation
  5. Investigating the Effect of BCG Vaccine on Preventing COVID-19 Infection in Healthcare Staff Exposed to SARS-CoV-2
  6. Phase 1, safety, immunogenicity and dose finding for two strengths of 0.5 × 10^6 and 2.5 × 10^6 (TCID50) inactivated SARS-CoV-2 vaccine FAKHRAVAC (MIVAC) injected in two schedules of two doses, 2 and 3 weeks apart in healthy adults aged 18-55 years: a randomized, double blind, placebo controlled, clinical trial
  7. Comparison of humoral response in half and full dose of BNT162b2 vaccinated in people under 55 years of age
  8. A Clinical trial to evaluate the immunogenicity and safety of Omicron-Based CovIran Barkat vaccine as a third injection dose in vaccinated population over 18 years of age
  9. Effect of Gluten-free Regimen on the Quality of Life and Disease Severity of Ulcerative Colitis Patients; A Randomised Controlled Clinical Trial
  10. Phase 2 trial of safety and immunogenicity of 10 micro gram inactivated SARS-CoV-2 vaccine (FAKHRAVAC), two doses two weeks apart in adults aged 18-70 years: a randomized, double-blind, placebo-controlled, clinical trial
duration of mechanical ventilation in ICU admitted COVID 19 patients Design: Permuted block randomization (...) without blinding (phase 1 trial with 33 patients) Settings and conduct: 66 intubated patients with COVID-19 infection who admitted to the Intensive care unit (Baharloo hospital, Tehran) were randomized to
IRCTID: IRCT20210225050495N1
Study aim: Evaluation of the effect of using probiotic products to control the symptoms of hospitalized patients with definite diagnosis of COVID-19 Design: Phase 3 trial, Randomized trial, with block randomization on 60 covid-19 patients, in two groups control and intervention, follow for 14 days. Settings
IRCTID: IRCT20161206031255N4
Study aim: evaluation of the effect of treatment regimen contains Intrefron beta-1-b on the Covid 19 patients compared with those patients who received treatment regimen without interfron. Design: Open label, controlled and paralleled non-randomized clinical trial with control group phase 2-3 on 150
IRCTID: IRCT20201001048894N1
Study aim: Evaluation of the effect of GCSF injection in treatment of COVID-19 patients with lymphopenia (less than 1000) in Kosar Hospital Design: Clinical trial with control group, Randomized, Single (...) /Inclusion and exclusion criteria: Inclusion criteria: Patients with Covid 19; Conscious consent of the
IRCTID: IRCT20200502047268N1
  1. Evaluation the effect of granulocyte colony stimulating factor on fertility rate in infertile woman with unexplained infertility
  2. Comparison of the effect of prophylactic granulocyte colony-stimulating factor versus placebo on neutrophil count before chemotherapy on children with malignant neuroblastoma
  3. Comparison of GCSF administration in two methods of daily GCSF versus every other day on cell blood count and patients' pain in patients with breast cancer
  4. Effectiveness Study Comparing Granulocyte colony-stimulating factor (GCSF) with Placebo for Improvement of Sensory, Motor and Sphincter Function in Patients with Spinal cord Injury
  5. A comparative study of the effect of platelet-rich plasma (PRP) and granulocyte colony-stimulating factor (GCSF) in patients with recurrent implantation failure
  6. The comparing granulocyte colony stimulating factor , intra muscular and intra uterine form on fertilization at women with idiopathic infertility in intra uterine insemination.
  7. Effect of subcutaneous Granulocyte colony stimulating factor (G-CSF) versus placebo on in-vitro fertilization (IVF) results in patients with recurrent implantation failure (RIF): A double-blind, randomized, controlled, clinical trial
  8. Comparing the expression levels of BMP15, GDF9, FLT1 and HIF1 genes in granulosa cells of women with poor ovarian response under GCSF treatment with women with poor ovarian response receiving normal saline: a clinical trial
  9. A clinical trial to compare the effectiveness of the granulocyte colony-stimulating factor with standard treatment in non-M3 acute myelogenous leukemia patients
  10. The effect of intrauterine infusion of Granulocyte Colony-Stimulating Factor (G-CSF) on endometrial thickness in frozen embryo transfer
Study aim: The effectiveness of Cognitive-Behavioral Crisis Intervention Package on COVID-19 Fear Symptoms, Improving Quality of Life and Improving Mental Health in Corona Patients Design: Clinical trial with control group Settings and conduct: Imam Khomeini, Ziaian and Masih Daneshvari hospitals
IRCTID: IRCT20200509047360N1
reduction of pulmonary complications of COVID-19 in patients Design: Clinical trial with control group (...) criteria: Entry requirements: Covid 19 patients with CT scan confirmation and clinical symptoms Conditions of non-entry: Covid 19 patients have severe underlying diseases Intervention groups: Intervention
IRCTID: IRCT20200404046935N1
  1. The effect of naproxen on the healing process of patients with COVID-19
  2. Evaluation of the efficacy of melatonin tablets as auxiliary medication in accelerating the improvement of the COVID-19 symptoms and clinical findings: A double-blind randomized and placebo controlled trial
  3. Evaluation of efficacy of pharmacotherapy treatment of COVID- 19 infection using oral Levamisole and Formoterol+Budesonide inhaler and comparison of this treatment protocol with standard national treatment of the disease
  4. Evaluation of the efficacy and side effects of combination therapy of Kaletra and Hydroxychloroquine in comparison with Atazanavir / Ritonavir and Hydroxychloroquine in the treatment of patients with COVID-19
  5. Effect of atorvastatin on mortality rate and symptom improvement in hospitalized patients with COVID-19
  6. Evaluation of the effectiveness of microemulsion containing extracted squalene based on oilseeds for the treatment of COVID-19
  7. Effect of Intravenous immunoglobulin (IVIG) versus Kaletra (lopinavir and ritonavir) tablets in patients with acute respiratory infection (COVID-19): A clinical trial studies
  8. Safety and efficacy of “Hydroxychloroquine + Azithromycin + Naproxen + Prednisolone” and “Hydroxychloroquine + Azithromycin + Naproxen” regimens in comparison with “Hydroxychloroquine + kaletra” on the need for intensive care unit treatment in patients with COVID-19; a randomized, multicenter, parallel groups, open label study
  9. Evaluation of safety and efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra on the need for intensive care unit treatment in patients with COVID-19; a randomized, multicenter, parallel groups, open label study
  10. Comparison of vitamin D3 and N-acetylcysteine prescription in COVID19 patients and their effect on recovery process
Study aim: Evaluating efficacy and safety of Hydroxychloroquine + Lopinavir or Atazanavir/ritonavir combination in patients with COVID-19 Design: This is a non-blinded, single group clinical trial. Settings (...) /Inclusion and exclusion criteria: Inclusion criteria: Patients with highly suspected or confirmed COVID-19
IRCTID: IRCT20100228003449N30
  1. Evaluation of safety and efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra on the need for intensive care unit treatment in patients with COVID-19; a randomized, multicenter, parallel groups, open label study
  2. Comparing the effectiveness of Lopinavir/Ritonavir/Hydroxychloroquine and Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine treatment regiments in moderate to severe COVID-19 patients
  3. Evaluating the efficacy and safety of intravenous immunoglobulin (IVIG) in COVID-19 patients
  4. Safety and efficacy of “Hydroxychloroquine + Azithromycin + Naproxen + Prednisolone” and “Hydroxychloroquine + Azithromycin + Naproxen” regimens in comparison with “Hydroxychloroquine + kaletra” on the need for intensive care unit treatment in patients with COVID-19; a randomized, multicenter, parallel groups, open label study
  5. Safety and Effectiveness of azithromycin in Patients with COVID-19 Referred to zeiaeian Hospital : A clinical trial study
  6. Evaluation of Atazanavir/Ritonavir effect on COViD-19 patients treatment in comparison with Lopinavir / Ritonavir
  7. Comparison of the efficacy and safety of Atazanavir/Ritonavir plus Hydroxychloroquine regimen with Lopinavir/Ritonavir plus Hydroxychloroquine regimen in patients with moderate COVID-19, A randomized, double-blind study
  8. Evaluation the efficacy and safety of Sitagliptin administration in patients with COVID-19
  9. Evaluation of the efficacy and safety of Umifenovir in the treatment of hospitalized patients with covid-19: A randomized clinical trial
  10. Efficacy and safety evaluation of therapeutic regimen of lopinavir/ritonavir and interferon beta 1b in patients with COVID-19
Study aim: Evaluating efficacy and safety of interferone β-1a in the treatment COVID-19 infection Design: This is a non-blinded randomized clinical trial. Settings and conduct: This study will be done (...) criteria: 18-75 years old persons Highly suspected of confirmed COVID-19 infection Exclusion criteria
IRCTID: IRCT20100228003449N28
criteria: 18-75 years old persons with highly suspected or confirmed COVID-19 Exclusion criteria (...) Study aim: Evaluating efficacy and safety of interferone β-1b (IFN β-1b) in the treatment of COVID-19 Design: This is a non-blinded randomized clinical trial.Included patients will be assigned to
IRCTID: IRCT20100228003449N27
Study aim: Evaluting the therapeutic and adverse effects of Interferon beta 1-a subcutaneous administration in patients with new Coronavirus (COVID-19) Design: Non-controlled clinical trial Settings and (...) confirmed COVID-19 who are in severe phase and did not have chronic kidney or liver diseases and are not
IRCTID: IRCT20151227025726N12
Study aim: Determination of the addition of melatonin to routine treatment on treatment outcomes and the quality of sleep in COVID-19 patients Design: The present study will be a clinical trial study with a parallel design and without blinding. Settings and conduct: The study will be conducted in
IRCTID: IRCT20200411047030N1
Loading...